ZX 8177
Alternative Names: ZX-8177Latest Information Update: 05 Jan 2026
At a glance
- Originator Nanjing Zenshine Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 26 Dec 2025 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Recurrent, Inoperable/Unresectable, Second-line therapy or greater) in China (PO) (NCT07310134)
- 14 Apr 2023 Pharmacodynamics data from a preclinical in Cancer presented at the 114th Annual Meeting of the American Association for Cancer ResearchSession (AACR-2023)
- 02 Mar 2023 Nanjing Zenshine Pharmaceuticals plans clinical trial in Solid tumours in 2023 (Nanjing Zenshine Pharmaceuticals pipeline, February 2023)